Intracerebral infusion of DOPAC decreases striatal dopamine

Ramin Shiekhattar, M. Behnam Ghasemzadeh, Ralph N. Adams

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The purpose of this study was to determine whether elevated levels of 3,4-dihydroxyphenylacetic acid (DOPAC), the major metabolite of dopamine (DA) in the brain, could decrease the DA content in the striatum. Levels of DA were determined by high pressure liquid chromatography with electrochemical detection (HPLCEC) in the striatum of male rats 24 h following a single intracerebral administration of DOPAC into the right striatum. DOPAC at 16.8 μg reduced the DA content of the infused side by 17%, p = 0.01. In contrast, infusion of 1.68 Mg of DOPAC or the vehicle had no effect on striatal DA levels. Coapplication of the antioxidant, ascorbic acid, at 0.2 mg/ml with 16.8 Mg of DOPAC prevented the decrease in DA content. Furthermore, infusion of 18.2 μg of homovanillic acid (HVA), the product of DOPAC methylation, had no effect on striatal DA. These results indicate that DOPAC may undergo autoxidation in vivo to produce neurotoxic species which may result in reduction of striatal DA. Formation of such an autoxidation product(s) of endogenous DOPAC was verified in the extracellular fluid of striatal slices in vitro.

Original languageEnglish (US)
Pages (from-to)891-896
Number of pages6
JournalBrain Research Bulletin
Volume29
Issue number6
DOIs
StatePublished - 1992
Externally publishedYes

Fingerprint

Corpus Striatum
Dopamine
Acids
3,4-Dihydroxyphenylacetic Acid
Homovanillic Acid
Extracellular Fluid
Methylation
Ascorbic Acid
Antioxidants
High Pressure Liquid Chromatography
Brain

Keywords

  • Autoxidation
  • Caudate
  • Free radicals
  • Parkinson's disease
  • Quinones
  • Toxicity

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Intracerebral infusion of DOPAC decreases striatal dopamine. / Shiekhattar, Ramin; Behnam Ghasemzadeh, M.; Adams, Ralph N.

In: Brain Research Bulletin, Vol. 29, No. 6, 1992, p. 891-896.

Research output: Contribution to journalArticle

Shiekhattar, Ramin ; Behnam Ghasemzadeh, M. ; Adams, Ralph N. / Intracerebral infusion of DOPAC decreases striatal dopamine. In: Brain Research Bulletin. 1992 ; Vol. 29, No. 6. pp. 891-896.
@article{181264d7fb194af8836ca6ba02d006fc,
title = "Intracerebral infusion of DOPAC decreases striatal dopamine",
abstract = "The purpose of this study was to determine whether elevated levels of 3,4-dihydroxyphenylacetic acid (DOPAC), the major metabolite of dopamine (DA) in the brain, could decrease the DA content in the striatum. Levels of DA were determined by high pressure liquid chromatography with electrochemical detection (HPLCEC) in the striatum of male rats 24 h following a single intracerebral administration of DOPAC into the right striatum. DOPAC at 16.8 μg reduced the DA content of the infused side by 17{\%}, p = 0.01. In contrast, infusion of 1.68 Mg of DOPAC or the vehicle had no effect on striatal DA levels. Coapplication of the antioxidant, ascorbic acid, at 0.2 mg/ml with 16.8 Mg of DOPAC prevented the decrease in DA content. Furthermore, infusion of 18.2 μg of homovanillic acid (HVA), the product of DOPAC methylation, had no effect on striatal DA. These results indicate that DOPAC may undergo autoxidation in vivo to produce neurotoxic species which may result in reduction of striatal DA. Formation of such an autoxidation product(s) of endogenous DOPAC was verified in the extracellular fluid of striatal slices in vitro.",
keywords = "Autoxidation, Caudate, Free radicals, Parkinson's disease, Quinones, Toxicity",
author = "Ramin Shiekhattar and {Behnam Ghasemzadeh}, M. and Adams, {Ralph N.}",
year = "1992",
doi = "10.1016/0361-9230(92)90161-P",
language = "English (US)",
volume = "29",
pages = "891--896",
journal = "Brain Research Bulletin",
issn = "0361-9230",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Intracerebral infusion of DOPAC decreases striatal dopamine

AU - Shiekhattar, Ramin

AU - Behnam Ghasemzadeh, M.

AU - Adams, Ralph N.

PY - 1992

Y1 - 1992

N2 - The purpose of this study was to determine whether elevated levels of 3,4-dihydroxyphenylacetic acid (DOPAC), the major metabolite of dopamine (DA) in the brain, could decrease the DA content in the striatum. Levels of DA were determined by high pressure liquid chromatography with electrochemical detection (HPLCEC) in the striatum of male rats 24 h following a single intracerebral administration of DOPAC into the right striatum. DOPAC at 16.8 μg reduced the DA content of the infused side by 17%, p = 0.01. In contrast, infusion of 1.68 Mg of DOPAC or the vehicle had no effect on striatal DA levels. Coapplication of the antioxidant, ascorbic acid, at 0.2 mg/ml with 16.8 Mg of DOPAC prevented the decrease in DA content. Furthermore, infusion of 18.2 μg of homovanillic acid (HVA), the product of DOPAC methylation, had no effect on striatal DA. These results indicate that DOPAC may undergo autoxidation in vivo to produce neurotoxic species which may result in reduction of striatal DA. Formation of such an autoxidation product(s) of endogenous DOPAC was verified in the extracellular fluid of striatal slices in vitro.

AB - The purpose of this study was to determine whether elevated levels of 3,4-dihydroxyphenylacetic acid (DOPAC), the major metabolite of dopamine (DA) in the brain, could decrease the DA content in the striatum. Levels of DA were determined by high pressure liquid chromatography with electrochemical detection (HPLCEC) in the striatum of male rats 24 h following a single intracerebral administration of DOPAC into the right striatum. DOPAC at 16.8 μg reduced the DA content of the infused side by 17%, p = 0.01. In contrast, infusion of 1.68 Mg of DOPAC or the vehicle had no effect on striatal DA levels. Coapplication of the antioxidant, ascorbic acid, at 0.2 mg/ml with 16.8 Mg of DOPAC prevented the decrease in DA content. Furthermore, infusion of 18.2 μg of homovanillic acid (HVA), the product of DOPAC methylation, had no effect on striatal DA. These results indicate that DOPAC may undergo autoxidation in vivo to produce neurotoxic species which may result in reduction of striatal DA. Formation of such an autoxidation product(s) of endogenous DOPAC was verified in the extracellular fluid of striatal slices in vitro.

KW - Autoxidation

KW - Caudate

KW - Free radicals

KW - Parkinson's disease

KW - Quinones

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=0026492462&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026492462&partnerID=8YFLogxK

U2 - 10.1016/0361-9230(92)90161-P

DO - 10.1016/0361-9230(92)90161-P

M3 - Article

C2 - 1473020

AN - SCOPUS:0026492462

VL - 29

SP - 891

EP - 896

JO - Brain Research Bulletin

JF - Brain Research Bulletin

SN - 0361-9230

IS - 6

ER -